title: Autoimmune and autoinflammatory mechanisms in uveitis.
abstract: The eye, as currently viewed, is neither immunologically ignorant nor sequestered from the systemic environment. The eye utilises distinct immunoregulatory mechanisms to preserve tissue and cellular function in the face of immune-mediated insult; clinically, inflammation following such an insult is termed uveitis. The intra-ocular inflammation in uveitis may be clinically obvious as a result of infection (e.g. toxoplasma, herpes), but in the main infection, if any, remains covert. We now recognise that healthy tissues including the retina have regulatory mechanisms imparted by control of myeloid cells through receptors (e.g. CD200R) and soluble inhibitory factors (e.g. alpha-MSH), regulation of the blood retinal barrier, and active immune surveillance. Once homoeostasis has been disrupted and inflammation ensues, the mechanisms to regulate inflammation, including T cell apoptosis, generation of Treg cells, and myeloid cell suppression in situ, are less successful. Why inflammation becomes persistent remains unknown, but extrapolating from animal models, possibilities include differential trafficking of T cells from the retina, residency of CD8(+) T cells, and alterations of myeloid cell phenotype and function. Translating lessons learned from animal models to humans has been helped by system biology approaches and informatics, which suggest that diseased animals and people share similar changes in T cell phenotypes and monocyte function to date. Together the data infer a possible cryptic infectious drive in uveitis that unlocks and drives persistent autoimmune responses, or promotes further innate immune responses. Thus there may be many mechanisms in common with those observed in autoinflammatory disorders.
authors.affiliation: National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University Hospitals Bristol NHS, Foundation Trust, and University of Bristol, Bristol, UK.
authors.forename: Richard W
authors.initials: RW
authors.lastname: Lee
authors.forename: Lindsay B
authors.initials: LB
authors.lastname: Nicholson
authors.forename: H Nida
authors.initials: HN
authors.lastname: Sen
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Lai
authors.initials: L
authors.lastname: Wei
authors.forename: Robert B
authors.initials: RB
authors.lastname: Nussenblatt
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Dick
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology* / Q000473:pathology; D015551:Autoimmunity; D006801:Humans; D058990:Molecular Targeted Therapy; D022423:Myeloid Cells / Q000276:immunology / Q000378:metabolism; D049490:Systems Biology / Q000379:methods; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D014605:Uveitis / Q000276:immunology* / Q000473:pathology / Q000628:therapy